

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai MicroPort MedBot (Group) Co., Ltd.**

**上海微创医疗机器人(集团)股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2252)**

## **VOLUNTARY ANNOUNCEMENT**

### **TOUMAI LAPAROSCOPIC SURGICAL ROBOT OBTAINED APPROVAL FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA FOR MULTIDISCIPLINARY REGISTRATION**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Toumai four-arm laparoscopic surgical robot (the “**Toumai**”), which is solely developed by the Group, applying to laparoscopic surgeries in departments of urinary surgery, general surgery, gynecologic surgery and thoracic surgery, has obtained approval for launch from the National Medical Products Administration of China (the “**NMPA**”).

#### **ABOUT TOUMAI**

Toumai, a core product of the Company, is a laparoscopic surgical robot designed and developed by the Group for a wide range of surgical procedures, which enables complex surgeries by adopting a minimally invasive approach. The agility of robotic arms allows greater precision in operations, enhances the safety of surgery and reduces surgeon fatigue. Sitting comfortably at the console, a surgeon views an immersive 3D HD image of the surgical field and manipulates the surgical instruments inside the patient’s body by controlling the robotic arms. Toumai provides surgeons with a range of motions analogous to those of human wrists, while filtering out the tremors inherent in human hands.

## **IMPACT ON THE COMPANY**

The application for Toumai’s multidisciplinary registration has been approved by NMPA, which is of great significance for the Group’s commercialisation process and business development. Up to now, Toumai has accumulatively completed more than 1,400 robot-assisted clinical trial surgeries in departments such as urinary surgery, hepatobiliary surgery, gastrointestinal surgery, thoracic surgery, gynecologic surgery, thyroid and breast surgery department in more than 40 hospitals in 20 provinces across the country. With the commercialisation application of Toumai in multidisciplinary aspect, the Group will continue to adhere to medical-industrial cooperation to provide more accurate, efficient and low-risk medical solutions for doctors and patients, and keep practising its original belief of “Make surgery easier, safer and less invasive”.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.**

By order of the Board  
**Shanghai MicroPort MedBot (Group) Co., Ltd.**  
**Mr. Sun Hongbin**  
*Chairman*

Shanghai, China, 25 October 2023

*As at the date of this announcement, the executive director of the Company is Dr. He Chao, the non-executive directors of the Company are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive directors of the Company are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.*